Navigation Links
Forest Laboratories, Inc. and Daiichi Sankyo, Inc. Announce the Termination of the AZOR Co-Promotion Agreement
Date:5/12/2008

NEW YORK and PARSIPPANY, N.J., May 12 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX), a U.S.-based pharmaceutical company, and Daiichi Sankyo, Inc. today announced that they have terminated their co-promotion agreement for AZOR(TM)* (amlodipine and olmesartan medoxomil), Daiichi Sankyo's fixed-dose combination of two antihypertensives, the calcium channel blocker amlodipine besylate and the angiotensin receptor blocker olmesartan medoxomil. Forest will record a one-time charge of $44.1 million which is composed of a one-time payment to Daiichi Sankyo of $26.6 million related to the termination and $17.5 million related to the unamortized portion of the initial upfront payment.

(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO )

The AZOR agreement is the second co-promotion agreement for the two companies. A previous agreement signed in 2002 by Forest to co-promote Benicar(R) (olmesartan medoxomil) and Benicar HCT(R) (olmesartan medoxomil-hydrochlorothiazide) is currently still in force. That agreement specified a co-promotion period, which has been extended to end on May 31, 2008, and a residual period where Forest will continue to receive income from Benicar(R) and Benicar HCT(R) profits, which doesn't expire until March 31, 2014.

Forest has determined that the resources it has allocated to the AZOR co-promotion will be better utilized in providing additional support for Forest's currently marketed products.

Beginning July 1, 2008, Daiichi Sankyo will take sole responsibility for the promotion of AZOR. The company has both expanded its cardiovascular sales capability in recent years and is adding ad
'/>"/>

SOURCE Forest Laboratories, Inc.; Daiichi Sankyo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
2. Forest Laboratories, Inc. Announces Positive Results of Memantine Study of Once-Daily Formulation
3. Forest Laboratories, Inc. and Merz Pharma GmbH & Co. KgaA File Additional Lawsuit Against Several Companies for Patent Infringement
4. Forest and Cypress Announce Submission of New Drug Application for Milnacipran for the Treatment of Fibromyalgia Syndrome
5. BioSpace Launches 3rd Edition of BioForest(TM) Bioscience Marketing Campaign
6. Drugs from Johnson & Johnson/Basilea and Forest Are the Most Promising Antibiotics in the Community-Acquired Pneumonia Pipeline
7. Nanotube forests grown on silicon chips for future computers, electronics
8. Forest Laboratories Lexapro and Generics-Dominated Fluoxetine Lead First-Line Therapy in the Treatment for Major Depression
9. Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration
10. Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
11. Clontech Laboratories, Inc. Releases the ProteoTuner(TM) Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 24, 2014  Vermillion, Inc. (Nasdaq:   ... disease, announced today that the Company closed its ... Investment Management, Jack W. Schuler , Birchview ... were $10.5 million, before offering expenses.  The proceeds ... corporate purposes. Under the terms of ...
(Date:12/24/2014)... GMO corn cases filed across the ... in the process of being consolidated in a Kansas ... In Re: Syngenta AG MIR 162 Corn Litigation, MDL ... District of Kansas. , Management of the Syngenta GMO ... U.S. District Judge John W. Lungstrum.* , As a ...
(Date:12/24/2014)... Bethesda, MD (PRWEB) December 23, 2014 ... signed into law H.R. 83, the Omnibus and ... the first time, made hydrocephalus a condition eligible ... Research Programs (CDMRP) administered by the Department of ... conjunction with its allies on Capitol Hill, is ...
(Date:12/24/2014)... December 23, 2014 Nashville Fertility Center ... elected treasurer for the American Society for Reproductive Medicine ... and research in reproductive medicine. In his new ... on the executive board and will have a voice ... Hill has actively supported ASRM since 1984 when he ...
Breaking Biology Technology:Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3
... PALO ALTO, Calif., Feb. 20 CV Therapeutics, Inc. ... board of directors has thoroughly reviewed and rejected the ... acquire CV Therapeutics at a price of $16.00 per ... its independent financial and legal advisors, the CV Therapeutics ...
... Nyenrode Business,Universiteit has awarded a Honorary Doctoral degree ... microeconomics, competitive strategy and cluster,theory. Professor Porter is ... of strategy and the world,s most influential thought ... Professor Porter will receive,the Honorary Doctorate on Wednesday ...
... $0.90 to $1.10 for 2009 and $1.50 to $1.70 for 2010PITTSBURGH, ... announced its financial results for the three and twelve months ended ... to $1.10 for 2009 and $1.50 to $1.70 for 2010. , ... Adjusted diluted EPS of $0.26 and $0.80 ...
Cached Biology Technology:CV Therapeutics' Board of Directors Rejects Astellas Unsolicited Proposal 2CV Therapeutics' Board of Directors Rejects Astellas Unsolicited Proposal 3CV Therapeutics' Board of Directors Rejects Astellas Unsolicited Proposal 4Nyenrode Honorary Doctorate for Professor Michael E. Porter 2Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 2Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 3Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 4Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 5Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 6Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 7Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 8Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 9Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 10Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 11Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 12Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 13Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 14Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 15Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 16Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 17
(Date:12/17/2014)... Dec. 15, 2014 Research and Markets ... of the "Samsung Galaxy S5 - Home ... to their offering. ... different sensing technology than the iPhone 5S, Samsung ... in its product. The Galaxy S5 ...
(Date:12/17/2014)... 2014 Research and Markets ( ... "Global Chemical Sensor Market 2015-2019" report ... http://photos.prnewswire.com/prnh/20130307/600769 One major trend upcoming ... medical sensors in biomedical applications. Chemical sensors help ... correct diagnosis during surgical procedures. The Global Chemical ...
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of the ... to their offering. One major ... of multimodal biometric systems. Multimodal biometric systems utilize ... verification and identification purposes. This helps to reduce ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... to be particularly prone to global warming caused by ... greenhouse gases. Now, a University of Utah study finds ... north: the Arctic's well-known haze ?made of particulate pollution ... better able to trap heat. , The effect makes ...
... dioxide from fossil fuel burning are dramatically altering ... that secrete skeletal structures and support oceanic biodiversity. ... effects of increased atmospheric carbon dioxide on these ... research for determining the extent of the impacts. ...
... stem cells, prized for their astonishing ability to apparently transform ... identities in part by interacting with their surroundings - even ... dish, University of Florida scientists report. , Using an animal ... Brain Institute have begun to answer one of the most ...
Cached Biology News:Pollutant haze heats the Arctic 2Pollutant haze heats the Arctic 3Pollutant haze heats the Arctic 4Report warns about carbon dioxide threats to marine life 2Report warns about carbon dioxide threats to marine life 3Medium is the message for stem cells in search of identities 2Medium is the message for stem cells in search of identities 3
... ImmEdge Pen, a hydrophobic barrier pen for ... for use with frozen or paraffin-embedded tissue ... Pen provides a heat-stable, water-repellent barrier that ... sections, prevents mixing of reagents when differentially ...
... Covance's BCIP/NBT Chromogen system ... Tetrazolium] chromogen in a single ... reacts in the presence of ... purple staining with minimal background ...
... CellBIND surface is produced by a patented ... surface giving more consistent, even cell attachment, ... cell attachment and growth uunder difficult conditions, ... CellBIND may provide a more ecominic alternative ...
SphingoStripsTM contain fifteen different biologically active, nitrocellulose-immobilized lipids at 100 pmol per spot, which can be assayed for protein binding and specificity using a simple blot ove...
Biology Products: